Endocrine Abstracts

Objetive: The change of treatment of liraglutide 1.8 mg to dapagliflozin or canaglifonzin 100 mg in patients with optimal glycemic control and stabilization weight loss, achieves progression in weight loss and improves the metabolic control of the patient with tipo 2 diabetes (DM-2). Our objective is to evaluate if there are differences in metabolic control and progression of weight loss in patients treated with canagliflozin 100 mg or dapagliflozin.

Patients and methods: Retrospective descriptive study: patients with DM-2 treated with metformin and liraglutide 1.8 mg, optimal metabolic control which after weight stabilization, liraglutide is suspended and treatment with canagliflozin 100 mg (group 1) or dapagliflozin (group 2) is initiated. Variables analyzed baseline and at 6 months after treatment change: age, sex, time of diabetes evolution, Body mass index (BMI), abdominal perimeter (BP), systolic blood pressure (SBP), diastolic blood pressure (DBP), lipid profile and uric acid (UA). Statistical analysis: comparing proportions with the chi-squared and comparing means with Student’s test.

Results: Thirty-three patients (group 1: 18; group 2: 15). Baseline characteristics were similar in both groups. Results at 6 months of treatment change:

Conclusions: We did not find differences in metabolic control and progression of weight loss in patients treated with canagliflozin 100 mg or dapagliflozin after stabilization with liraglutide 1.8 mg.